Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Massachusetts General Hospital
Chinese PLA General Hospital
University of Washington
University of Washington
City of Hope Medical Center
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
University of Chicago
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
City of Hope Medical Center
Dana-Farber Cancer Institute
St. Jude Children's Research Hospital
University of Washington
Baptist Health South Florida
Malaghan Institute of Medical Research
Alliance for Clinical Trials in Oncology
Case Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Medical University of South Carolina
St. Jude Children's Research Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dartmouth-Hitchcock Medical Center
Essen Biotech
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Mayo Clinic
St. Jude Children's Research Hospital
Institute of Hematology & Blood Diseases Hospital, China
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
Gustave Roussy, Cancer Campus, Grand Paris
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Medical College of Wisconsin
Mayo Clinic
University of Wisconsin, Madison
Massachusetts General Hospital
City of Hope Medical Center
University of Michigan Rogel Cancer Center
The Second Affiliated Hospital of Fujian Medical University